@ShahidNShah
Sharecare Launches VR Program to Bring Innovation to Exercise
Sharecare launches Get Active, a new virtual reality program to help employers encourage exercise among their workforces in a fun. Digital health company Sharecare launches Get Active, a new virtual reality program to help employers encourage exercise among their workforces in a fun, approachable, and accessible way. In a pilot with its customer Lennar Corporation, one of the nation’s leading homebuilders, Sharecare’s Get Active program for Meta Quest 2 yielded strong results for both healthy and high-risk Associates. In a pilot conducted in late 2022 with Lennar Corporation, Sharecare’s Get Active program generated promising results for their Associates, including those diagnosed with or at the greatest risk of developing diseases such as anxiety and depression, cancer, diabetes, and musculoskeletal disorders. Among high-risk participants, the pilot with Lennar yielded an engagement rate of 82% and a 280% increase in average weekly exercise minutes per person compared to pre-program.
Medigy Insights
Sharecare has developed a new virtual reality program called "Get Active" to promote exercise among employees. A pilot study with Lennar Corporation showed promising results, with an engagement rate of 82% and a 280% increase in weekly exercise minutes per person. The Get Active program has potential as an effective tool to improve physical activity levels among employees.
Continue reading at hitconsultant.net
Make faster decisions with community advice
- Digital Health Predictions: Uncertainty Will Trigger Innovation In 2023
- Measuring the return from pharmaceutical innovation 2021
- Do’s and Don’ts of Creating Digital Experiences
- Innovation Could Help Health Systems Meet Consumer Expectations
- Innovation in personal health data: Leading companies in automated healthcare billing and payment system
Next Article
-
Measuring the return from pharmaceutical innovation 2021
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and …